Latest Cantel Medical (CMN) Headlines Nephros a
Post# of 78
Posted On: 03/14/2014 12:56:58 PM
Latest Cantel Medical (CMN) Headlines
Nephros and Mar Cor Purification Announce Distribution Agreement
PR Newswire - Tue Mar 11, 3:10PM CDT
Nephros, Inc. (OTCQB:NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and Mar Cor Purification, a wholly owned subsidiary of Cantel Medical Corp., announced today that the companies have signed a non-exclusive distributor agreement to distribute Nephros's dialysis ultrafilters to U.S. and Canadian dialysis clinics.
Cantel Medical Reports EPS Of $0.27 vs. $0.25 On 12% Sales Increase For Second Quarter Ended January 31, 2014
PR Newswire - Tue Mar 11, 7:00AM CDT
CANTEL MEDICAL CORP. (NYSE:CMN) reported net income of $11,126,000, or $0.27 per diluted share, on a 12% increase in sales to a record $119,042,000 for the second quarter ended January 31, 2014. This compares with net income of $10,452,000, or $0.25 per diluted share, on sales of $106,363,000 for the second quarter ended January 31, 2013. For the six months ended January 31, 2014, the Company reported record net income of $22,311,000, or $0.54 per diluted share, on a 15% increase in sales to a record $237,314,000. This compares with net income of $20,028,000, or $0.49 per diluted share, on sales of $206,044,000 for the six months ended January 31, 2013. Results for the prior year's second quarter and six months ended January 31, 2013 include $0.01 in net favorable adjustments related to acquisition accounting fair value adjustments partially offset by severance and recruiting costs.
Cantel Medical Corp. to Host Second Quarter Earnings Webcast Live on Tuesday, March 11, 2014
ACCESSWIRE - Mon Mar 10, 1:11PM CDT
LITTLE FALLS, NJ / ACCESSWIRE / March 10, 2014 / Cantel Medical Corp. (CMN) will host a live webcast to discuss the results of the second quarter 2014, to be held Tuesday, March 11, 2014 at 11:00 AM Eastern Time.
Sterilization Equipment and Disinfectants Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
M2 - Fri Mar 07, 3:20AM CST
Research and Markets (http://www.researchandmarkets.com/research/z899cm/sterilization) has announced the addition of the "Sterilization Equipment and Disinfectants Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering 'Sterilization Equipment and Disinfectants Market (By Sterilization Equipment Type - Heat Sterilization, Low Temperature Sterilization, Filtration Sterilization and Radiation Sterilization,By Disinfectants Type-Low, Intermediate and High level and Oxidizing and Non-Oxidizing and By Applications- Medical Devices, Pharmaceuticals and Life-Sciences) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019' "Sterilization equipment and disinfectants are essential procedures for infection control in healthcare facilities such as hospitals, clinics and laboratories. Increase in hospital acquired infections has compelled medical professionals to take strict regulatory actions to cure these infections with the use of various sterilization equipment and disinfectants. This factor will trigger the growth of sterilization equipment and disinfectants market during the forecast period. In addition, rise in geriatric population and increase in the number of surgeries performed at hospitals and clinics will further drive the growth of this market. The market for sterilization equipment can be segmented as: by product (heat, low temperature, radiation and filtration sterilization) and by application (life sciences, medical devices and pharmaceuticals). The disinfectants market has been segmented based on types (low, intermediate and high level, oxidizing and non-oxidizing disinfectants). The report includes market estimations in terms of revenue (USD million) for the global sterilization equipment and disinfectants market for the period 2011 to 2019, considering 2012 as the base year. The report also provides the compounded annual growth rate (% CAGR) for the forecast period 2013 to 2019 for all the aforementioned segments and sub segments. In addition, current market trends and recent developments have been taken into consideration while determining the growth rate of the global sterilization equipment and disinfectants market. Key Topics Covered: Introduction Executive Summary Market Overview Global Sterilization Equipment Market, By Product, 2011 - 2019 (USD Million) Global Disinfectants Market, By Type, 2011 - 2019 (USD Million) Global Sterilization Equipment and Disinfectants Market, By Applications, 2011 - 2019 (USD Million) Global Sterilization Equipment and Disinfectants Market, by Geography, 2011 - 2019 (USD Million) Recommendations Company Profiles Companies Mentioned - 3M - Advanced Sterilization Products Services, Inc. - Belimed AG - Cantel Medical Corp. - CISA Group - Getinge Group - Kimberley-Clark Corporation - Matachana Group - Nordion, Inc. - SAKURA SI CO., LTD. - STERIS Corporation - Synergy Health Plc - TSO3, Inc. For more information visit http://www.researchandmarkets.com/research/z8...rilization About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Cantel Medical Corp. to Present at the Sidoti & Company LLC 18th Annual Emerging Growth Institutional Investor Forum
PR Newswire - Thu Mar 06, 11:44AM CST
CANTEL MEDICAL CORP. (NYSE:CMN) announced today that Andrew A. Krakauer, President & CEO, will be presenting at the Sidoti & Company, LLC 18th Annual Emerging Growth Institutional Investor Forum. The formal presentation is scheduled for 10:00 AM ET on Monday, March 17, 2014 at the Grand Hyatt Hotel, New York. In addition, Mr. Krakauer and Seth Yellin, Senior VP-Corporate Development, will be available for separate one-on-one meetings during the day.
Cantel Medical Enters Into $250 Million Revolving Credit Facility
PR Newswire - Wed Mar 05, 1:53PM CST
CANTEL MEDICAL CORP. (NYSE: CMN), today announced that it has entered into an amended and restated credit facility which established new terms under its revolving credit facility with its existing bank group led by Bank of America, N.A., and including Wells Fargo Bank, N.A. and PNC Bank, N.A.
Cantel Medical Corp. To Hold Conference Call To Discuss Results For Its Second Quarter Ended January 31, 2014
PR Newswire - Tue Mar 04, 10:28AM CST
CANTEL MEDICAL CORP. (NYSE: CMN) will release the results for its second quarter ended January 31, 2014 on Tuesday, March 11 before the market opens, and hold a conference call to discuss the results at 11:00 AM ET. Participating in the call will be Charles M. Diker, Chairman; Andrew A. Krakauer, President and CEO; Jorgen B. Hansen, Executive Vice President and COO; Craig A. Sheldon, Senior Vice President, CFO and Treasurer; and Seth Yellin, Senior Vice President-Corporate Development.
Cantel Medical Announces Novel Sterilization Process Receives ISO Registration
PR Newswire - Tue Feb 25, 11:41AM CST
Cantel Medical Corp. (NYSE: CMN) announces that the REVOX® Sterilization Solutions business is now registered to the EN ISO 13485:2003 quality standards. The room temperature, Peracetic Acid/Hydrogen Peroxide (PAA) vacuum vapor process enables effective sterilization of heat and/or chemical sensitive medical, drug delivery, diagnostic, and implantable devices that may not be well-suited to other sterilization processes.
Hospital Acquired Disease Testing Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
M2 - Tue Feb 18, 3:59AM CST
Research and Markets (http://www.researchandmarkets.com/research/tc2bz6/hospital_acquired) has announced the addition of the "Hospital Acquired Disease Testing Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. Nosocomial infections, most commonly called as hospital acquired diseases or healthcare associated infections (HAI),are acquired by patients during their stay in hospitals. Since the last decade, remarkable prevalence of nosocomial infections has been observed worldwide and its morbidity rate is rapidly growing. Patients with weak immune system, those exposed to improper hygiene conditions in hospitals, the high neonatal population in developing countries and elderly patients worldwide are highly susceptible to nosocomial infection. Aging of population is one of the major factors that has increased the incidence rate of hospital acquired diseases worldwide. Growing morbidity rate has resulted in a rise in nosocomial infection mortality globally. Contraction of nosocomial infection prolongs hospital stay of patients and ultimately the cost to the patients as well as the hospital increases. Though various diagnostic tests are available in the market for detection of infectious microorganisms, approximately 70% of such pathogens are becoming resistant to at least one of the anti-bacterial drugs most commonly used in nosocomial infection treatments, thus creating a challenge for healthcare professionals to treat such patients. Increasing resistance to commonly used antibiotics has created a demand for microorganism specific detection test for better assessment by healthcare professionals in order to provide appropriate treatment. Molecular diagnostics, PCR, microarrays and solid phase hybridization are some of the major techniques used for the diagnosis of nosocomial infections. The development of nucleic acid testing (NAT) diagnostic products and related platforms have enabled the entry of many players in the hospital acquired disease testing market. Nosocomial infections are mainly categorized into six types depending on the kind of infection, namely, hospital acquired pneumonia, urinary tract infection, blood stream infection, surgical site infection, MRSA (Methicillin-resistant Staphylococcus aureus)infection and other miscellaneous variants which include gastro intestinal infection, cardiovascular infections, respiratory infections and infections related to joints. Occurrence of hospital acquired UTI is highest in all types of nosocomial infections,leading to the highest market share by revenue of hospital acquired UTI testing segment in the overall HAI testing market. Geographically, North America dominates the global hospital acquired disease testing market and is followed by Europe. Government initiatives to control and prevent nosocomial infection in these regions and their rigorous implementation to reduce the disease morbidity rate is driving the growth of nosocomial infection testing market. Asia-Pacific is a lucrative market for HAI testing owing to increased incidence of hospital acquired disease testing in countries like China and India and the growing need to reduce healthcare expenditure by both, the healthcare institutions and patients equally. Contribution of Asian countries to the hospital acquired disease testing market is expected to increase further as the medical tourism industry flourishes in this region. Key Topics Covered - Introduction - Executive Summary - Market Overview - Global Hospital Acquired Disease Testing, by Infection Type - Global Hospital Acquired Disease Testing, by Geography - Recommendations - Company Profiles Companies Mentioned - Abbott Laboratories - Alere - bioMerieux - Becton, Dickinson and Company - Cantel Medical - Cepheid - Diatherix Laboratories - F. Hoffman-La Roche - Gen-Probe - Life Technologies - Meridian Bioscience - Nordion - Qiagen For more information visit http://www.researchandmarkets.com/research/tc...l_acquired About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Cantel Medical Acquires Sterilator Company, Inc.
PR Newswire - Wed Jan 08, 7:30AM CST
CANTEL MEDICAL CORP. (NYSE: CMN), through its Crosstex subsidiary, has further expanded its sterility assurance monitoring business with the acquisition of Sterilator Company, Inc. Based in Cuba, NY, Sterilator Company is a high-quality manufacturer of biological indicators and supplies for sterility assurance products, which are used to accurately monitor the effectiveness of sterilization processes. Sterilator serves both the medical and industrial markets, and has been a long-time supplier of self-contained biological indicators, dual species spore strips and culture media to our dental and hospital healthcare disposable business.
Education Management Announces Appointments to Executive Leadership Team
PR Newswire - Tue Jan 07, 11:19AM CST
Education Management Corporation (NASDAQ: EDMC) today announced that James (Jim) Hobby has been appointed to the newly created position of executive vice president (EVP) of Operational Services & Support and Charles Restivo has been named president of The Art Institutes.
Financial Results, Conference Presentation Schedule, Clinical Trial Initiation, Recognition, and Dividend Payment - Research Report on Cantel, Chimerix, Verastem, Amedisys, and Ensign Group
PR Newswire - Wed Dec 25, 7:00AM CST
Editor Note: For more information about this release, please scroll to bottom.
Earnings Look Back: Cantel Medical Is Down 2.5% Since Reporting Quarterly Results 2 Weeks Ago (CMN)
Comtex SmarTrend(R) - Mon Dec 23, 7:00AM CST
Two weeks ago on December 5th, 2013 Cantel Medical (NYSE:CMN) reported earnings and analysts, on average, expected earnings of $0.24 on sales of $113.0 million. Cantel Medical actually reported earnings of $0.27 per share on sales of $118.3 million, beating EPS estimates by $0.03 and beating revenue estimates by $5.3 million. Since the company's report, shares of Cantel Medical have fallen from $35.41 to $34.53, representing a loss of 2.5% in the past 18 days.
Post Earnings Update: Cantel Medical Has Sunk 4.4% Lower in Past Week (CMN)
Comtex SmarTrend(R) - Mon Dec 16, 7:04AM CST
11 days ago, on December 5th, 2013, Cantel Medical (NYSE:CMN) reported its earnings. Analysts, on average, expected earnings of $0.24 per share on sales of $113.0 million. Cantel Medical actually reported earnings of $0.27 per share on sales of $118.3 million, beating EPS estimates by $0.03 and beating revenue estimates by $5.3 million. Shares of Cantel Medical have slipped from $35.41 to $33.84, representing a loss of 4.4%, since the company reported earnings 11 days ago.
Shares of CMN Up 29.8% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Dec 06, 9:09AM CST
SmarTrend identified an Uptrend for Cantel Medical (NYSE:CMN) on September 17th, 2013 at $27.51. In approximately 3 months, Cantel Medical has returned 29.77% as of today's recent price of $35.70.
Cantel Medical Reports 19% Sales Growth And EPS Of $0.27 vs. $0.23 For The First Quarter Ended October 31, 2013
PR Newswire - Thu Dec 05, 7:30AM CST
CANTEL MEDICAL CORP. (NYSE: CMN) reported a 17% increase in net income to a record $11,185,000, or $0.27 per diluted share, on a 19% increase in sales to a record $118,272,000 for the first quarter ended October 31, 2013. This compares with net income of $9,576,000, or $0.23 per diluted share, on sales of $99,681,000 for the first quarter ended October 31, 2012.
Webcast Alert: Cantel Medical Corp. Announces First Quarter and 2014 Earnings Call
ACCESSWIRE - Mon Dec 02, 10:08AM CST
Little Falls, NJ - (ACCESSWIRE - December 2, 2013) - Cantel Medical Corp. (CMN) announces the following live Webcast, to discuss the results of the First Quarter and 2014 Earnings Call, to be held December 5, 2013 @ 11:00 AM Eastern.
Uptrend Call Working As Cantel Medical Stock Rises 38.2% (CMN)
Comtex SmarTrend(R) - Fri Nov 29, 9:25AM CST
SmarTrend identified an Uptrend for Cantel Medical (NYSE:CMN) on September 17th, 2013 at $27.51. In approximately 2 months, Cantel Medical has returned 38.17% as of today's recent price of $38.01.
Cantel Medical To Present At The 25th Annual Piper Jaffray Healthcare Conference
PR Newswire - Tue Nov 26, 1:59PM CST
CANTEL MEDICAL CORP. (NYSE:CMN) announced today that Andrew A. Krakauer, President & CEO, will be presenting at the 25th Annual Piper Jaffray Healthcare Conference at The New York Palace in New York. The formal presentation is scheduled for Tuesday, December 3, 2013 at 4:00 PM ET. In addition, Mr. Krakauer and Seth Yellin, Senior Vice President-Corporate Development, will be available for separate one-on-one meetings during the day.
Cantel Medical Corp. To Hold Conference Call To Discuss Results For Its First Quarter Ended October 31, 2013
PR Newswire - Tue Nov 26, 11:18AM CST
CANTEL MEDICAL CORP. (NYSE:CMN) will release the results for its first quarter ended October 31, 2013 on Thursday, December 5 before the market opens, and hold a conference call to discuss the results at 11:00 AM ET. Participating in the call will be Charles M. Diker, Chairman; Andrew A. Krakauer, President and CEO; Jorgen B. Hansen, Executive Vice President and COO; Craig A. Sheldon, Senior Vice President, CFO and Treasurer; and Seth Yellin, Senior Vice President-Corporate Development.
Nephros and Mar Cor Purification Announce Distribution Agreement
PR Newswire - Tue Mar 11, 3:10PM CDT
Nephros, Inc. (OTCQB:NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and Mar Cor Purification, a wholly owned subsidiary of Cantel Medical Corp., announced today that the companies have signed a non-exclusive distributor agreement to distribute Nephros's dialysis ultrafilters to U.S. and Canadian dialysis clinics.
Cantel Medical Reports EPS Of $0.27 vs. $0.25 On 12% Sales Increase For Second Quarter Ended January 31, 2014
PR Newswire - Tue Mar 11, 7:00AM CDT
CANTEL MEDICAL CORP. (NYSE:CMN) reported net income of $11,126,000, or $0.27 per diluted share, on a 12% increase in sales to a record $119,042,000 for the second quarter ended January 31, 2014. This compares with net income of $10,452,000, or $0.25 per diluted share, on sales of $106,363,000 for the second quarter ended January 31, 2013. For the six months ended January 31, 2014, the Company reported record net income of $22,311,000, or $0.54 per diluted share, on a 15% increase in sales to a record $237,314,000. This compares with net income of $20,028,000, or $0.49 per diluted share, on sales of $206,044,000 for the six months ended January 31, 2013. Results for the prior year's second quarter and six months ended January 31, 2013 include $0.01 in net favorable adjustments related to acquisition accounting fair value adjustments partially offset by severance and recruiting costs.
Cantel Medical Corp. to Host Second Quarter Earnings Webcast Live on Tuesday, March 11, 2014
ACCESSWIRE - Mon Mar 10, 1:11PM CDT
LITTLE FALLS, NJ / ACCESSWIRE / March 10, 2014 / Cantel Medical Corp. (CMN) will host a live webcast to discuss the results of the second quarter 2014, to be held Tuesday, March 11, 2014 at 11:00 AM Eastern Time.
Sterilization Equipment and Disinfectants Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
M2 - Fri Mar 07, 3:20AM CST
Research and Markets (http://www.researchandmarkets.com/research/z899cm/sterilization) has announced the addition of the "Sterilization Equipment and Disinfectants Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering 'Sterilization Equipment and Disinfectants Market (By Sterilization Equipment Type - Heat Sterilization, Low Temperature Sterilization, Filtration Sterilization and Radiation Sterilization,By Disinfectants Type-Low, Intermediate and High level and Oxidizing and Non-Oxidizing and By Applications- Medical Devices, Pharmaceuticals and Life-Sciences) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019' "Sterilization equipment and disinfectants are essential procedures for infection control in healthcare facilities such as hospitals, clinics and laboratories. Increase in hospital acquired infections has compelled medical professionals to take strict regulatory actions to cure these infections with the use of various sterilization equipment and disinfectants. This factor will trigger the growth of sterilization equipment and disinfectants market during the forecast period. In addition, rise in geriatric population and increase in the number of surgeries performed at hospitals and clinics will further drive the growth of this market. The market for sterilization equipment can be segmented as: by product (heat, low temperature, radiation and filtration sterilization) and by application (life sciences, medical devices and pharmaceuticals). The disinfectants market has been segmented based on types (low, intermediate and high level, oxidizing and non-oxidizing disinfectants). The report includes market estimations in terms of revenue (USD million) for the global sterilization equipment and disinfectants market for the period 2011 to 2019, considering 2012 as the base year. The report also provides the compounded annual growth rate (% CAGR) for the forecast period 2013 to 2019 for all the aforementioned segments and sub segments. In addition, current market trends and recent developments have been taken into consideration while determining the growth rate of the global sterilization equipment and disinfectants market. Key Topics Covered: Introduction Executive Summary Market Overview Global Sterilization Equipment Market, By Product, 2011 - 2019 (USD Million) Global Disinfectants Market, By Type, 2011 - 2019 (USD Million) Global Sterilization Equipment and Disinfectants Market, By Applications, 2011 - 2019 (USD Million) Global Sterilization Equipment and Disinfectants Market, by Geography, 2011 - 2019 (USD Million) Recommendations Company Profiles Companies Mentioned - 3M - Advanced Sterilization Products Services, Inc. - Belimed AG - Cantel Medical Corp. - CISA Group - Getinge Group - Kimberley-Clark Corporation - Matachana Group - Nordion, Inc. - SAKURA SI CO., LTD. - STERIS Corporation - Synergy Health Plc - TSO3, Inc. For more information visit http://www.researchandmarkets.com/research/z8...rilization About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Cantel Medical Corp. to Present at the Sidoti & Company LLC 18th Annual Emerging Growth Institutional Investor Forum
PR Newswire - Thu Mar 06, 11:44AM CST
CANTEL MEDICAL CORP. (NYSE:CMN) announced today that Andrew A. Krakauer, President & CEO, will be presenting at the Sidoti & Company, LLC 18th Annual Emerging Growth Institutional Investor Forum. The formal presentation is scheduled for 10:00 AM ET on Monday, March 17, 2014 at the Grand Hyatt Hotel, New York. In addition, Mr. Krakauer and Seth Yellin, Senior VP-Corporate Development, will be available for separate one-on-one meetings during the day.
Cantel Medical Enters Into $250 Million Revolving Credit Facility
PR Newswire - Wed Mar 05, 1:53PM CST
CANTEL MEDICAL CORP. (NYSE: CMN), today announced that it has entered into an amended and restated credit facility which established new terms under its revolving credit facility with its existing bank group led by Bank of America, N.A., and including Wells Fargo Bank, N.A. and PNC Bank, N.A.
Cantel Medical Corp. To Hold Conference Call To Discuss Results For Its Second Quarter Ended January 31, 2014
PR Newswire - Tue Mar 04, 10:28AM CST
CANTEL MEDICAL CORP. (NYSE: CMN) will release the results for its second quarter ended January 31, 2014 on Tuesday, March 11 before the market opens, and hold a conference call to discuss the results at 11:00 AM ET. Participating in the call will be Charles M. Diker, Chairman; Andrew A. Krakauer, President and CEO; Jorgen B. Hansen, Executive Vice President and COO; Craig A. Sheldon, Senior Vice President, CFO and Treasurer; and Seth Yellin, Senior Vice President-Corporate Development.
Cantel Medical Announces Novel Sterilization Process Receives ISO Registration
PR Newswire - Tue Feb 25, 11:41AM CST
Cantel Medical Corp. (NYSE: CMN) announces that the REVOX® Sterilization Solutions business is now registered to the EN ISO 13485:2003 quality standards. The room temperature, Peracetic Acid/Hydrogen Peroxide (PAA) vacuum vapor process enables effective sterilization of heat and/or chemical sensitive medical, drug delivery, diagnostic, and implantable devices that may not be well-suited to other sterilization processes.
Hospital Acquired Disease Testing Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
M2 - Tue Feb 18, 3:59AM CST
Research and Markets (http://www.researchandmarkets.com/research/tc2bz6/hospital_acquired) has announced the addition of the "Hospital Acquired Disease Testing Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. Nosocomial infections, most commonly called as hospital acquired diseases or healthcare associated infections (HAI),are acquired by patients during their stay in hospitals. Since the last decade, remarkable prevalence of nosocomial infections has been observed worldwide and its morbidity rate is rapidly growing. Patients with weak immune system, those exposed to improper hygiene conditions in hospitals, the high neonatal population in developing countries and elderly patients worldwide are highly susceptible to nosocomial infection. Aging of population is one of the major factors that has increased the incidence rate of hospital acquired diseases worldwide. Growing morbidity rate has resulted in a rise in nosocomial infection mortality globally. Contraction of nosocomial infection prolongs hospital stay of patients and ultimately the cost to the patients as well as the hospital increases. Though various diagnostic tests are available in the market for detection of infectious microorganisms, approximately 70% of such pathogens are becoming resistant to at least one of the anti-bacterial drugs most commonly used in nosocomial infection treatments, thus creating a challenge for healthcare professionals to treat such patients. Increasing resistance to commonly used antibiotics has created a demand for microorganism specific detection test for better assessment by healthcare professionals in order to provide appropriate treatment. Molecular diagnostics, PCR, microarrays and solid phase hybridization are some of the major techniques used for the diagnosis of nosocomial infections. The development of nucleic acid testing (NAT) diagnostic products and related platforms have enabled the entry of many players in the hospital acquired disease testing market. Nosocomial infections are mainly categorized into six types depending on the kind of infection, namely, hospital acquired pneumonia, urinary tract infection, blood stream infection, surgical site infection, MRSA (Methicillin-resistant Staphylococcus aureus)infection and other miscellaneous variants which include gastro intestinal infection, cardiovascular infections, respiratory infections and infections related to joints. Occurrence of hospital acquired UTI is highest in all types of nosocomial infections,leading to the highest market share by revenue of hospital acquired UTI testing segment in the overall HAI testing market. Geographically, North America dominates the global hospital acquired disease testing market and is followed by Europe. Government initiatives to control and prevent nosocomial infection in these regions and their rigorous implementation to reduce the disease morbidity rate is driving the growth of nosocomial infection testing market. Asia-Pacific is a lucrative market for HAI testing owing to increased incidence of hospital acquired disease testing in countries like China and India and the growing need to reduce healthcare expenditure by both, the healthcare institutions and patients equally. Contribution of Asian countries to the hospital acquired disease testing market is expected to increase further as the medical tourism industry flourishes in this region. Key Topics Covered - Introduction - Executive Summary - Market Overview - Global Hospital Acquired Disease Testing, by Infection Type - Global Hospital Acquired Disease Testing, by Geography - Recommendations - Company Profiles Companies Mentioned - Abbott Laboratories - Alere - bioMerieux - Becton, Dickinson and Company - Cantel Medical - Cepheid - Diatherix Laboratories - F. Hoffman-La Roche - Gen-Probe - Life Technologies - Meridian Bioscience - Nordion - Qiagen For more information visit http://www.researchandmarkets.com/research/tc...l_acquired About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Cantel Medical Acquires Sterilator Company, Inc.
PR Newswire - Wed Jan 08, 7:30AM CST
CANTEL MEDICAL CORP. (NYSE: CMN), through its Crosstex subsidiary, has further expanded its sterility assurance monitoring business with the acquisition of Sterilator Company, Inc. Based in Cuba, NY, Sterilator Company is a high-quality manufacturer of biological indicators and supplies for sterility assurance products, which are used to accurately monitor the effectiveness of sterilization processes. Sterilator serves both the medical and industrial markets, and has been a long-time supplier of self-contained biological indicators, dual species spore strips and culture media to our dental and hospital healthcare disposable business.
Education Management Announces Appointments to Executive Leadership Team
PR Newswire - Tue Jan 07, 11:19AM CST
Education Management Corporation (NASDAQ: EDMC) today announced that James (Jim) Hobby has been appointed to the newly created position of executive vice president (EVP) of Operational Services & Support and Charles Restivo has been named president of The Art Institutes.
Financial Results, Conference Presentation Schedule, Clinical Trial Initiation, Recognition, and Dividend Payment - Research Report on Cantel, Chimerix, Verastem, Amedisys, and Ensign Group
PR Newswire - Wed Dec 25, 7:00AM CST
Editor Note: For more information about this release, please scroll to bottom.
Earnings Look Back: Cantel Medical Is Down 2.5% Since Reporting Quarterly Results 2 Weeks Ago (CMN)
Comtex SmarTrend(R) - Mon Dec 23, 7:00AM CST
Two weeks ago on December 5th, 2013 Cantel Medical (NYSE:CMN) reported earnings and analysts, on average, expected earnings of $0.24 on sales of $113.0 million. Cantel Medical actually reported earnings of $0.27 per share on sales of $118.3 million, beating EPS estimates by $0.03 and beating revenue estimates by $5.3 million. Since the company's report, shares of Cantel Medical have fallen from $35.41 to $34.53, representing a loss of 2.5% in the past 18 days.
Post Earnings Update: Cantel Medical Has Sunk 4.4% Lower in Past Week (CMN)
Comtex SmarTrend(R) - Mon Dec 16, 7:04AM CST
11 days ago, on December 5th, 2013, Cantel Medical (NYSE:CMN) reported its earnings. Analysts, on average, expected earnings of $0.24 per share on sales of $113.0 million. Cantel Medical actually reported earnings of $0.27 per share on sales of $118.3 million, beating EPS estimates by $0.03 and beating revenue estimates by $5.3 million. Shares of Cantel Medical have slipped from $35.41 to $33.84, representing a loss of 4.4%, since the company reported earnings 11 days ago.
Shares of CMN Up 29.8% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Dec 06, 9:09AM CST
SmarTrend identified an Uptrend for Cantel Medical (NYSE:CMN) on September 17th, 2013 at $27.51. In approximately 3 months, Cantel Medical has returned 29.77% as of today's recent price of $35.70.
Cantel Medical Reports 19% Sales Growth And EPS Of $0.27 vs. $0.23 For The First Quarter Ended October 31, 2013
PR Newswire - Thu Dec 05, 7:30AM CST
CANTEL MEDICAL CORP. (NYSE: CMN) reported a 17% increase in net income to a record $11,185,000, or $0.27 per diluted share, on a 19% increase in sales to a record $118,272,000 for the first quarter ended October 31, 2013. This compares with net income of $9,576,000, or $0.23 per diluted share, on sales of $99,681,000 for the first quarter ended October 31, 2012.
Webcast Alert: Cantel Medical Corp. Announces First Quarter and 2014 Earnings Call
ACCESSWIRE - Mon Dec 02, 10:08AM CST
Little Falls, NJ - (ACCESSWIRE - December 2, 2013) - Cantel Medical Corp. (CMN) announces the following live Webcast, to discuss the results of the First Quarter and 2014 Earnings Call, to be held December 5, 2013 @ 11:00 AM Eastern.
Uptrend Call Working As Cantel Medical Stock Rises 38.2% (CMN)
Comtex SmarTrend(R) - Fri Nov 29, 9:25AM CST
SmarTrend identified an Uptrend for Cantel Medical (NYSE:CMN) on September 17th, 2013 at $27.51. In approximately 2 months, Cantel Medical has returned 38.17% as of today's recent price of $38.01.
Cantel Medical To Present At The 25th Annual Piper Jaffray Healthcare Conference
PR Newswire - Tue Nov 26, 1:59PM CST
CANTEL MEDICAL CORP. (NYSE:CMN) announced today that Andrew A. Krakauer, President & CEO, will be presenting at the 25th Annual Piper Jaffray Healthcare Conference at The New York Palace in New York. The formal presentation is scheduled for Tuesday, December 3, 2013 at 4:00 PM ET. In addition, Mr. Krakauer and Seth Yellin, Senior Vice President-Corporate Development, will be available for separate one-on-one meetings during the day.
Cantel Medical Corp. To Hold Conference Call To Discuss Results For Its First Quarter Ended October 31, 2013
PR Newswire - Tue Nov 26, 11:18AM CST
CANTEL MEDICAL CORP. (NYSE:CMN) will release the results for its first quarter ended October 31, 2013 on Thursday, December 5 before the market opens, and hold a conference call to discuss the results at 11:00 AM ET. Participating in the call will be Charles M. Diker, Chairman; Andrew A. Krakauer, President and CEO; Jorgen B. Hansen, Executive Vice President and COO; Craig A. Sheldon, Senior Vice President, CFO and Treasurer; and Seth Yellin, Senior Vice President-Corporate Development.
(0)
(0)Cantel Medical Corp. (CMD) Stock Research Links
Scroll down for more posts ▼